Activities of Benzimidazole d - and l -Ribonucleosides in Animal Models of Cytomegalovirus Infections
Open Access
- 1 May 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (5) , 1749-1755
- https://doi.org/10.1128/aac.48.5.1749-1755.2004
Abstract
Since human cytomegalovirus (HCMV) does not infect or replicate in nonhuman cells and tissues, there are few animal models currently available for evaluation of antiviral therapies for these infections. In the present studies, we utilized two different models in which severe combined immunodeficient (SCID) mice were implanted with human fetal tissue that was subsequently infected with HCMV. In one model, human fetal retinal tissue was implanted into the anterior chamber of the SCID mouse eye, and in the second, human fetal thymus and liver (thy/liv) tissues were implanted under the kidney capsule. After the implants were established, they were infected with 2,000 to 9,000 PFU of HCMV. To determine the efficacy of three benzimidazole nucleosides, 2-bromo-5,6-dichloro-(1-β- d -ribofuranosyl)benzimidazole (BDCRB), GW275175X (175X), and GW257406X (1263W94, maribavir [MBV]) treatment was initiated 24 h after infection of the implants and continued for 28 days. Treatment consisted of either placebo, 25 mg of ganciclovir (GCV)/kg of body weight administered intraperitoneally (i.p.) twice daily, 33 or 100 mg of BDCRB/kg administered i.p. twice daily, or 75 mg of either MBV or 175X/kg administered orally twice daily. GCV was effective in both models, inhibiting HCMV infection by 5- to 3,000-fold. In the retinal tissue model, MBV and BDCRB reduced HCMV replication about fourfold through 21 days postinfection compared with results for the vehicle control. In the thy/liv tissue model, all three benzimidazole nucleosides were effective in inhibiting HCMV replication by approximately 30- to 3,000-fold in comparison to the vehicle control. These data indicate that the benzimidazole nucleosides were efficacious in these animal models and suggest that this class of compounds should be active against the various HCMV infections that occur in the immunocompromised host.Keywords
This publication has 33 references indexed in Scilit:
- Bis-Anthracycline Antibiotics Inhibit Human Immunodeficiency Virus Type 1 TranscriptionAntimicrobial Agents and Chemotherapy, 2004
- Mechanism of Action of the Ribopyranoside Benzimidazole GW275175X against Human CytomegalovirusAntimicrobial Agents and Chemotherapy, 2004
- Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of ActionAntimicrobial Agents and Chemotherapy, 2002
- Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus ReplicationAntimicrobial Agents and Chemotherapy, 2002
- Inhibition of Ganciclovir-Susceptible and -Resistant Human Cytomegalovirus Clinical Isolates by the Benzimidazole l -Riboside 1263W94Clinical and Diagnostic Laboratory Immunology, 2001
- Replication of Human Cytomegalovirus in Severe Combined Immunodeficient Mice Implanted with Human Retinal TissueThe Journal of Infectious Diseases, 2001
- Design, Synthesis, and Antiviral Activity of Certain 2,5,6-Trihalo-1-(.beta.-D-ribofuranosyl)benzimidazolesJournal of Medicinal Chemistry, 1995
- Dramatic Interstrain Differences in the Replication of Human Cytomegalovirus in SCID-hu MiceThe Journal of Infectious Diseases, 1995
- Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigsAntiviral Research, 1990
- Effect of Acyclovir and Phosphonoformate on Cytomegalovirus Infection in Guinea PigsIntervirology, 1984